s 377

[This corrects the article DOI: 10.1371/journal.pone.0187294.].

Oral busulfan is an alkylating agent that provides good antileukemic activity and excellent CNS penetration. It was first introduced over 30 years ago by George Santos as an alternative to total body irradiation (TBI) for preallogeneic transplantation conditioning [1]. Since its introduction, it has had a mixed reputation. Oral busulfan (PO BU) proved an attractive alternative to TBI based on g...

BACKGROUND We describe the risk indicators for oral mucositis (OM) in paediatric oncology patients hospitalised in the Institut Gustave Roussy (Villejuif-Paris) and treated with alkylant chemotherapy with autologous peripheral blood progenitor cells. METHODS The sample was selected using PIGAS software. Three groups of subjects received different chemotherapy regimens: A. Melphalan, B. Busulf...

Hepsulfam (NSC 329680), a bifunctional alkylating agent structurally related to busulfan, has entered clinical trial based on its broader preclinical antitumor activity compared with that of busulfan and its i.v. formulation which may circumvent the many problems arising from the p.o. administration of busulfan, such as significant individual differences in bioavailability. In this Phase I stud...